Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.55 |
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.53 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.53 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.49 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.49 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.49 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.49 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70021 | 0.98 | HRH3 (0.56) | HRH3KDM1AHRH2HRH1USP2 | |
| SCHEMBL25013995 | 0.83 | KDM1A (0.51) | HRH3KDM1AHRH2HRH1PRKAA2 | |
| SCHEMBL20804360 | 0.82 | KCNJ1 (0.66) | HRH3USP2KCNJ1KCNH2CYP1A2 | |
| SCHEMBL28024576 | 0.82 | KCNJ1 (0.66) | HRH3USP2KCNJ1KCNH2CYP1A2 | |
| SCHEMBL647375 | 0.82 | HRH3 (0.57) | HRH3HRH2HRH1USP2PRKAA2 | |
| SCHEMBL15033028 | 0.82 | DRD2 (0.48) | HRH3KDM1AMAOAMAOB | |
| SCHEMBL14375216 | 0.82 | HRH3 (0.67) | HRH3HRH2HRH1USP2PRKAA2 | |
| SCHEMBL12533594 | 0.80 | DRD4 (0.53) | HRH3KDM1A | |
| Hydrochloric Acid SCHEMBL11533737 | 0.80 | MEN1 (0.58) | HRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2673496 | 0.80 | MEN1 (0.58) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| CN-106928211-A | Benzamide compound for treating dysbolism | 里格尔药品股份有限公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-104016980-B | For treating the benzamide compound of dysbolismus | 里格尔药品股份有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-103201267-B | AMPK-activating heterocyclic compounds and methods of use thereof | 里格尔药品股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012016217-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | HRH3 4418/4885HRH2 4345/4885HRH1 4360/4885 |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | HRH3 3498/4885HRH2 2680/4885HRH1 3146/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | HRH3 4418/4885HRH2 4345/4885HRH1 4360/4885 |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HRH3 2573/4885HRH2 2641/4885HRH1 2994/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HRH3 2573/4885HRH2 2641/4885HRH1 2994/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | HRH3 4418/4885HRH2 4345/4885HRH1 4360/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | HRH3 4418/4885HRH2 4345/4885HRH1 4360/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | HRH3 2547/4885HRH2 2532/4885HRH1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.